I
Ira Pastan
Researcher at Laboratory of Molecular Biology
Publications - 1304
Citations - 113191
Ira Pastan is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Immunotoxin & Pseudomonas exotoxin. The author has an hindex of 160, co-authored 1286 publications receiving 110069 citations. Previous affiliations of Ira Pastan include Heidelberg University & National Institutes of Health.
Papers
More filters
Patent
Target-specific, cytotoxic, recombinant pseudomonas exotoxin
TL;DR: In this article, a target-specific, cytotoxic, recombinant Pseudomonas exotoxin is described by inserting specific recognition molecules at specific cloning sites in at least domain III near the carboxyl terminus of the PE molecule.
Journal ArticleDOI
Expression of the Human Multidrug Resistance and Glucocerebrosidase cDNAs from Adeno-Associated Vectors: Efficient Promoter Activity of AAV Sequences and In Vivo Delivery via Liposomes
Marion Baudard,Terence R. Flotte,Josep M. Aran,Alain R. Thierry,Ira Pastan,Myung-Geol Pang,William G. Kearns,Michael M. Gottesman +7 more
TL;DR: The results demonstrate that the efficiency of liposomes as vehicles for in vitro and in vivo gene delivery, the advantages of AAV-vectors, and the use of MDR1 as a selectable marker might be successfully combined in gene therapy protocols.
Journal ArticleDOI
Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment.
Chuanchu Wu,Elaine Jagoda,Martin W. Brechbiel,Keith O. Webber,Ira Pastan,Otto Gansow,William C. Eckelman +6 more
TL;DR: The disulfide-linked fragment (dsFv) of the antibody to the alpha subunit of the IL2 receptor has been radiolabeled with a Ga-2-(p-SCN-Bz)-NOTA derivative linked through an isothiocyanato group to either the epsilon-amino group of lysine or the alpha-aminos group of the N-terminal amino acids to label the appropriate amino acid in a LMWP.
Book ChapterDOI
Display and selection of scFv antibodies on HEK-293T cells.
Mitchell Ho,Ira Pastan +1 more
TL;DR: A human cell display strategy to isolate high-affinity single-chain antibody fragments specific for CD22 for the treatment of B-cell malignancies using flow cytometry and human embryonic kidney 293T (HEK-293T) cells.
Journal ArticleDOI
In Vivo Drug-Selectable Genes: A New Concept in Gene Therapy
TL;DR: Preclinical studies in tissue culture and animal models, and ongoing clinical trials on transfer of chemoresistance genes to hematopoietic precursor cells of cancer patients are reviewed.